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Abstract
Background: Osteoporosis-associated fractures are of increasing importance in trauma surgery. Systematic diagnostics
and treatment of osteoporosis during a hospital stay, however, remain inadequate. Therefore, a specific algorithm for
diagnosing and treating osteoporosis in trauma surgery patients was developed based on the DVO (German Osteology
Society) guideline for osteoporosis from 2014.
Methods: In a first step, the individuals’ age and risk profile for osteoporosis is identified considering specific fractures
indicating osteoporosis and risk factors assessed by a specific questionnaire. In addition, physical activity, risk of falls,
dietary habits and the individuals’ medication are considered. Basic osteoporosis laboratory tests, a bone densitometry
by dual-energy X-ray absorptiometry (DXA) and, if needed, X-rays of the spine are carried out to identify prevalent
vertebral body fractures.
Results: Based on the treatment algorithm adapted to the new guidelines for osteoporosis in the majority of
proximal femoral fractures, treatment of osteoporosis could already be indicated without prior DXA. In case of
preexisting glucocorticoid therapy, a history of previous fractures or other risk factors according to the risk
questionnaire, the threshold of treatment has to be adjusted given the table of T-scores.
Conclusions: The treatment algorithm for diagnosing and treating osteoporosis in in-patient trauma surgery
patients can help identify high-risk patients systematically and efficiently. As a result, osteoporosis-associated
fractures or failure of osteosynthesis could be reduced, yet a prospective validation of the algorithm has to be
completed.
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Background
Osteoporosis is a frequent underlying disease in elderly
patients with fractures following low-energy trauma which
is often identified too late or not at all, and therefore,
trauma surgeons play a key role in the investigation and
management of the disease.
Manifest osteoporosis leads to limited life expectancy
and quality of life. Osteoporotic fractures are often
accompanied by the loss of independence. The preva-
lence of osteoporosis in female patients >75 years old is
estimated at 59.2% [1]. It is assumed that in the Federal
Republic of Germany 6.3–7.8 million people suffer from
osteoporosis [1, 2]. Up to 27% of the patients have
already suffered a fracture. Patients who have had mul-
tiple fractures run an 85% risk of suffering another frac-
ture within a year if not treated with drugs [3]. However,
only 21% of osteoporosis patients in Germany receive
guideline-oriented treatment [1]. A possible explanation
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for inadequate diagnostics and treatment of osteoporosis
is certainly the increasing complexity of a guideline-
oriented procedure. The DVO guideline creates trans-
parency in view of the increasingly complex scientific
evidence. Adapted to the current osteoporosis guideline of
the DVO (Dachverband Osteologie = German Osteology
Society) from 2014 [4], a diagnostics and treatment
algorithm for treating inpatients in trauma surgery has
been developed in order to eliminate the deficit in treat-
ment. This algorithm has been developed to make use of
existing scientific evidence pragmatically in trauma
surgery on a daily basis. The aims of this algorithm are to
improve on the one hand the deficit in diagnosing osteo-
porosis as an underlying disease in trauma patients and,
on the other hand, to reduce the deficit in treatment of
osteoporosis as a systemic skeletal disorder to reduce
following osteoporotic fractures.
Methods
Identification of patients related to osteoporosis
Patients with fracture
In general, a distinction has to be made between patients
with and without fractures typical of osteoporosis (thor-
acic and lumbar vertebral fractures, proximal femoral
fractures, proximal humerus fractures and distal radius
fractures) [5]. Additional clarification is advisable in
female patients >50 and male patients >60 years old who
have already suffered a fracture indicating osteoporosis.
In a previous examination of trauma surgical patients
with such a fracture, osteoporosis was established in
56.2% of women >50 and 59% of men >60 years old [6].
Patients without fracture
It is always important to establish whether women >70
and men >80 years old are suffering from osteoporosis,
whereas for younger patients, this only makes sense if
there are specific risk factors (DVO guideline 2014).
Specific risk questionnaires are a reliable and cost-effective
method of determining the individual risk [7]. The individ-
ual risk of fractures can be determined reliably from the
evidence-based risk factors. The FRAX and the Q-Fracture
score, for example, are internationally accepted means for
calculating osteoporosis-associated risks of fractures [8, 9].
The risk model of the DVO represents a further means for
calculating the risk of fractures. We developed a risk ques-
tionnaire based on this (Fig. 1). The yes/no questions are
clearly comprehensible for any patient and offer only one
possible answer. Once one of the questions is answered by
“yes”, the risk profile is assumed to be positive and it has
to be established whether the patient is suffering from
osteoporosis or not. In a later step of the algorithm, the
risk profile is taken up again and will influence the thera-
peutic decision based on the T-score determined by dual-
energy X-ray absorptiometry (DXA) (if necessary, the
treatment threshold has to be raised by +0.5). In addition,
individual physical activity, risk of falling, dietary habits
and current medication will be included. In clinical prac-
tice, this enables the doctor in charge to decide individually
how to diagnose and treat osteoporosis in a time-saving
and cost-effective way.
Diagnostics of patients related to osteoporosis
Evaluation of basic laboratory tests
The first step of the entire diagnostic process leading to
the diagnosis of osteoporosis is the laboratory diagnos-
tics (Fig. 2). As the decrease in bone density in terms of
secondary osteoporosis may be caused by hitherto
unknown co-morbidities or changes in the metabolism, it
is important to establish the most important risk factors
that can be identified in a laboratory [10]. In addition to
that, basic laboratory tests contribute to checking import-
ant contraindications for medical treatment. Table 1
shows a list of important co-morbidities caused by specific
changes in laboratory findings.
Indication of vertebral body fractures
Vertebral body fractures are a common sign of osteopor-
osis. Prevalent vertebral fractures are associated with
high risk of impaired function and additional fractures.
Due to static changes such as kyphosis and the shortening
of the affected vertebral sections, they may cause numer-
ous clinical symptoms and syndromes [11], like progres-
sive kyphosis of the thoracic spine (“dowagers hump”), the
loss of height >4–10 cm and typical skin folds appear that
run down the back laterally to the flanks, referred as “fir
tree phenomenon”. Often spinal compression fractures
occur clinically asymptomatically and without previous
trauma. They account for 11–15% of osteoporotic frac-
tures [12]. As a result, the risk of further vertebral body
fractures increases considerably [13]. Furthermore, degen-
erative changes in the vertebral column and vertebral frac-
tures have a significant influence on bone densitometry by
DXA, as such changes may lead to an incorrectly high
bone densitometry [14, 15].
Since up to 75% of vertebral fractures do not come to
clinical attention at the time of their occurrence, spine
imaging with X-ray is required for their detection. For
vertebral fracture assessment on standard lateral spine
radiographs, the Genant semiquantitative method is used
as the gold standard [16]. With this method, vertebral frac-
tures can be graduated from 0 (normal) up to III (severe).
Form and extent (loss of height) of the fracture were char-
acterized. Multiple vertebral body fractures I° (Genant) or
singular vertebral body fractures II–III° (Genant) in female
patients >50 and male patients >60 years old need specific
medical treatment, independent of the bone density mea-
sured by DXA according to the DVO guideline 2014. In
this respect, the morphology of the vertebral column plays
Neuerburg et al. Journal of Orthopaedic Surgery and Research  (2017) 12:86 Page 2 of 12
Fig. 1 Osteoporosis risk questionnaire
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Fig. 2 Osteoporosis diagnostic algorithm
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an important part in diagnosing and treating osteoporosis.
Therefore, the synopsis of clinical signs of vertebral frac-
tures and the severity of vertebral fractures according to
Genant play a very important role in our algorithm to start
immediately a specific treatment of osteoporosis.
Fractures of the femoral neck or pertrochanteric fractures
Proximal femoral fractures as femoral neck fractures and
pertrochanteric fractures are diagnosed by radiography.
For characterization of femoral neck fractures, the classi-
fication of Garden is frequently used. Pertrochanteric
fractures are classified by the AO/OTA classification. As
indicated in the osteoporosis algorithm, there is a spe-
cific link for “proximal femoral fractures”: according to
the published draft of the DVO guideline 2014, the indi-
cation for specific medical treatment of osteoporosis was
set for all patients with fractures of the femoral neck
and a T-score <−2 as well as for those with a low-trauma
pertrochanteric fracture (independent of the T-score).
This indication for treatment of osteoporosis was reduced
in the subsequently adopted version of the DVO guideline
2014 and replaced by the statement that treatment is gen-
erally indicated even without measuring bone density in
typical radiological and/or clinical aspects of proximal
femoral fractures [4]. In the authors’ opinion, however, the
above mentioned femoral fractures have a significant
relevance as a diagnostic criterion for the initiation of
osteoporosis treatment, because of the high risk of
mortality associated with these, the high risk of follow-
up fractures and the influence on the quality of life
connected with that [17].
This criterion was nevertheless taken up in the algo-
rithm, because it helps to significantly facilitate the start of
the treatment of osteoporosis in trauma surgical practice
(Fig. 2). Osteoporosis treatment with drugs initiated after
a proximal femoral fracture is accompanied by a signifi-
cant reduction in new fractures and optimised survival
[18]. The Working Group Geriatric Traumatology of the
German Society for Trauma Surgery (AG Alterstraumato-
logie der Deutschen Gesellschaft für Unfallchirurgie) pre-
dicts that the number of proximal femoral fractures
will rise dramatically by 351% by 2050 due to demo-
graphic development [19]. This estimate underlines the
importance of ascertaining the diagnosis for osteoporosis
mentioned above.
Bone densitometry
The definition of Osteoporosis by the World Health
Organisation (WHO) is characterized by using a densito-
metric definition based on areal bone mineral density
Table 1 List of most important causes related to changes in laboratory findings, according to the DVO guideline 2014 [4]
Laboratory parameter Diagnostic interest
Serum-calcium ↑Primary hyperparathyroidism, tumour hypercalcaemia
↓e.g. secondary hyperparathyroidism, malabsorption,
hypercalcaemia and hypocalcaemia as contraindications
for several drugs against osteoporosis
Serum-phosphate ↑Renal insufficiency stage IV
↑Secondary renal hyperparathyroidism
↓Malabsorption
Serum-sodium (optional) ↓Greater risk of vertebral and non-vertebral fractures
Alkaline phosphatase (AP) (serum) ↑e.g. osteomalacia
Gamma-GT For differential diagnosis of AP-increase caused by hepatitis,
evidence for coeliac disease or alcohol abuse (risk of falling)
Creatinine-clearance ↓Renal osteopathy
Severe renal insufficiency as contraindication for various drugs
ESR (erythrocyte sedimentation rate)/CRP
(C-reactive protein)
↑Differential diagnosis for inflammatory causes of vertebral body
deformities, inflammatory rheumatic diseases, multiple myeloma
full blood count Evidence of inflammatory and malignant diseases or coeliac disease
Serum-protein electrophoresis Evidence of monoclonal gammopathy or hypogammaglobulinaemia
as evidence of MGUS or multiple myeloma; polyclonal
hypergammglobulinaemia in systemic inflammatory diseases
TSH <0.3 mU/L caused endogenously or by L-Thyroxine medication
as a risk factor for fractures
If necessary, testosterone for men Testosterone deficiency
If necessary, 25-hydroxy-vitamin D3 in individual cases Vitamin D deficiency
If necessary, bone resorption parameter in
individual cases (inconsistent data for men)
Fracture risk due to a high rate of bone re-formation
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measured with DXA [20]. Due to this and solid data,
low costs and a low level of exposure to radiation, bone
densitometry by DXA is still used as the gold standard
for analysing bone density [21]. A decrease in bone
density raises the risk of an osteoporotic fracture [22].
Data for bone density in the area of the lumbar column
(lumbar column body 1–4) and of the proximal femur col-
lected during that process are compared with the data for
bone density in a standard control group (i.e. T-score).
Together with the age of the patient and the individual
risk factors, this score forms the basis for the decision for
a specific osteoporosis treatment. DXA as diagnostic part
can be found in our algorithm at different points: import-
ant for a pragmatic approach is from our point of view
that there are two important fractures (vertebral fractures
and proximal femoral fractures) where the diagnosis
osteoporosis is clear and a specific medication can be
started without initial DXA as diagnostic part.
Risk factors relevant for treatment
A large number of risk factors have significant influence
on the bone metabolism and the development of osteo-
porosis. In addition to the risk factors for the decision
for a specific osteoporosis treatment already mentioned
above, medical treatment with glucocorticoids should
also be considered; the risk of suffering an osteoporotic
vertebral body fracture during this treatment is signifi-
cantly increased [23]. Therefore, specific medical treat-
ment is already indicated when the T-score is ≤−1.5 and
when treated daily with 7.5 mg prednisolone (see Fig. 2
for T-score chart).
Individual fracture anamnesis is also of considerable
relevance for the risk of suffering further fractures [24].
According to the DVO risk calculation, this risk factor
leads to a raising of the treatment threshold by means of
the T-score by +1.0. Other risk factors may also lead to a
raising of the treatment threshold by +0.5 and are there-
fore to be collected consistently using the risk question-
naire mentioned above (Fig. 1) in order to make an
individual identification of osteoporosis according to the
attached T-score chart (Fig. 2) possible.
Treatment of osteoporosis
After having detected risk patients by means of our risk
questionnaire and having diagnosed osteoporosis ac-
cording to our algorithm, specific treatment of the
osteoporosis is initiated (Fig. 3). A negative impact on
the healing of fractures caused by anti-resorptive treat-
ment by bisphosphonates cannot be proved [25, 26].
Ingrowth of prostheses (also cemented ones) [27, 28] is
supported by anti-resorptive treatment. There are clin-
ical studies that show that the osteoanabolic treatment
of fractures with teriparatide has a positive influence on
the healing process [29, 30].
If there are any questions concerning treatment strat-
egies for complex osteological issues or for patients with a
serious course of the disease, we have an osteological team
constantly available for consultation by the colleagues on
the ward in our clinic.
When choosing a drug for specific treatment of osteo-
porosis, the specific registration for the relevant indication
and the lack of contraindications must be considered. The
basis for this is the latest expert information.
Basic treatment
According to the guidelines of the DVO, the basic treat-
ment stays the intake of 1000 mg calcium/day via nutri-
tion, supplemented by 800–1000 IU vitamin D/day as a
maintenance dose.
Vitamin D deficiency
A 25-hydroxy-vitamin D concentration in the serum
<50 nmol/l or <20 ng/ml is accompanied by a moder-
ately increased risk of proximal femoral fractures and
non-vertebral fractures in elderly men and post-
menopausal women [29–32]. The osteologically recom-
mended range for adequate treatment is a serum level of
30–150 ng/ml (75–375 nmol/l) [33–36]. The synthesis
of vitamin D3 in the skin under the impact of UV-light
decreases with age, which is due to less exposure to
sunlight and a reduction in the functioning of the skin
[34, 37, 38]. Because there is a high proportion of elderly
and very old people as patients in trauma surgery and
geriatric traumatology and because it is by definition a
question of manifest osteoporosis (with previous fracture),
we generally recommend that the 25-hydroxy-vitamin D
level in this group of patients be initially checked, in
accordance with the DVO decision in individual cases.
Studies show that only 7% of patients with a proximal
femoral fracture have a sufficient 25-OH-vitamin D level.
If hypovitaminosis D (with secondary hyperparathyr-
oidism) is proved, we recommend compensation with
20,000 IU Dekristol/week along with serum-calcium
check-ups until the 25-OH-vitamin D level is in the
desired area mentioned above (and the iPTH has nor-
malised). High-dose treatment with a single administra-
tion of 50,000 IU vitamin D is accompanied by a higher
risk of falling and fracture [39, 40].
It is important not to forget that vitamin D is a liposo-
luble vitamin that needs fat from nutrition for adequate
resorption. Therefore, we recommend that it is taken
with a meal or thereafter to avoid soberness.
Calcium supplementation
Calcium is found not only in milk and dairy products. A
good basis for a diet with a sufficient supply of calcium
for the patients is mineral water rich in calcium, con-
taining approximately 400–500 mg of calcium. This is
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Fig. 3 Osteoporosis treatment algorithm (adapted from Schray D et al. 2016 [51])
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also possible on a trauma surgery ward. It should be
possible to manage about 1000 mg of calcium in com-
bination with a balanced diet containing vegetables,
herbs and dairy products such as yoghurt, hard cheese
and curds. Of course, there are situations when this is
not possible (lactose or other intolerances). Then, an
adequate and individual supplementation with calcium is
necessary; thus, a total calcium intake of 1000 mg
calcium per day is recommended following either sup-
plementation or nutritional intake or a combination
thereof. If treated with glucocorticoids, a supplementation
with 1000 mg calcium/day is generally recommended.
Patients who have to ingest a proton pump inhibitor
(PPI) permanently are a special case. Instead of calcium
carbonate, calcium gluconate or calcium citrate is to be
administered. For the elderly (>65 years), the long-term
intake of a PPI in particular means a higher risk of
falling and therefore a higher risk of fracture-associated
in-patient treatment [41], decreased trabecular bone
mineral density [42], as well as a significantly increased
risk of vertebral fractures and hip fractures [43]. There-
fore, the indication for PPI treatment and the risk-
benefit ratio are to be regularly checked.
Specific medical treatment of osteoporosis
Strontium ranelates, SERMs (selective oestrogen recep-
tor modulators: ralixofene, bazedoxifene) and a hormone
replacement therapy (HRT) with oestrogens (possibly in
combination with a gestagen) are not suitable for use
(initiation of specific medical treatment) on a trauma
surgical ward due to a poor risk benefit ratio, e.g. risk of
thrombosis associated with oral HRT. The recom-
mended drugs for the treatment of osteoporosis are
listed in Tables 2 and 3.
Oral bisphosphonates
For the intake of oral bisphosphonate patients have to
be able to sit up straight for 30 min, renal function has
to be sufficiently good (GFR >30 ml/min) and the
expected compliance has to be high.
Before initiating anti-resorptive treatment it is essential
to look at the patient’s dental chart or at the condition of
the jaws (pressure sores) if the patient has dentures. It is
recommended that the dentist be informed about the
treatment. Regular visits to the dentist for check-ups are
also recommended [44].
If it is decided to initiate anti-resorptive treatment with
an oral bisphosphonate during a hospital stay, the com-
bination with a proton pump inhibitor (PPI) such as
omeprazole is problematic. The resorption rate in the
stomach is already very low to start with and is signifi-
cantly reduced or made impossible by the administration
of a PPI [45]. In view of currently available studies, we in
this case recommend risedronate 35 mg/week [46, 47].
It is possible to administer 150 mg p.o. of the oral bis-
phosphonate ibandronate once a month.
The intake frequency must also be considered in terms
of compliance; the lower the intake frequency, the better
the compliance tends to be [48].
IV-bisphosphonate
Bisphosphonates that are injected intravenously may be
used when the enteral administration of bisphosphonates is
not possible (see above). This requires a GFR >30 ml/min.
Zoledronate (5 mg/year) and ibandronate (3 mg/3 months)
are available for this. Zoledronate has been proved to reduce
the fracture rate and mortality significantly [49]. This is
only true, however, after a time interval of 2 weeks after
the operation of a proximal femoral fracture. At this point,
patients with an uneventful postoperative course are usu-
ally no longer on a trauma surgery ward. From an osteo-
logical point of view, it also makes sense to wait with the
administration of an iv-bisphosphonate until 6 weeks after
a fracture.
Teriparatide
Teriparatide (rhPTH 1–34: shortened, recombined form
of the human parathormone (1–84)) is an osteoanabolic
osteoporosis treatment method that leads to the (re-)
Table 3 Overview of the treatment efficiency of specific
osteoporosis treatment for post-menopausal women [4]
Compound Fewer vertebral
body fractures
Fewer
peripheral
fractures
Fewer proximal
femur fractures
Alendronate A A A
Denosumab A A A
Ibandronate A B –
Risedronate A A A
Zoledronate A A A
Teriparatide A B –
Table 2 Approval status of selected drugs for specific treatment
of osteoporosis
Compound Post-menopausal
women
Men >60 years
Alendronate 70 mg/week X –
Alendronate 10 mg/day X X
Risedronate 35 mg/week X X
Ibandronate oral
(150 mg/month)
and iv (3 mg/3 months
X –
Zoledronate iv 5 mg/year X X
Denosumab 60 mg sc/6 months X Xa
Teriparatide 20 ug sc/day for
max 24 months
X X
aMen with decreased bone density and higher risk of fractures
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augmentation of bone substance and that can reconstruct
the micro-architecture of the bone. The osteoanabolic
effect (stimulation of proliferation and differentiation of
osteoblasts) is achieved by the single application of a small
dose of 20 μg teriparatide per day (preferably in the eve-
nings) and, always at the same time, administered sub-
cutaneously by the patients themselves. Contraindications
are hypercalcaemia or severe renal insufficiency, Paget’s
disease or primary or secondary hyperparathyroidism.
Teriparatide is restricted to a maximum treatment duration
of 24 months.
Especially from a trauma surgical point of view, the
osteoanabolic mechanism of action of teriparatide has
on the whole a big advantage compared to anti-resorptive
drugs. However, due to its high price and the complex use
(daily subcutaneous administration by the patients them-
selves after a hospital stay), it is not a first choice drug. In
a serious course of manifest osteoporosis, teriparatide is
definitely to be considered and it has therefore been
implemented in our in-patient algorithm.
Denosumab
The activity of RANKL on the surface of osteoclasts is
specifically inhibited by the high affinity and specificity
of denosumab, a fully human, monoclonal antibody of
the immunoglobulin-isotype IgG2 that is applied sub-
cutaneously (60 mg/6 months). Denosumab inhibits the
binding of RANK-ligands to RANK (surface of osteo-
blasts) and therefore provides a therapeutic approach in
the treatment of osteoporosis and other diseases with
loss of bone mass.
It is not necessary to adjust the dose of denosumab for
patients suffering from renal dysfunction. Other advan-
tages are the easy subcutaneous administration every
6 months and the lack of febrile reactions in contrast to
iv-bisphosphonates. Before the beginning of treatment,
the calcium-serum level has to be standard. Patients are
to undergo a consistent treatment with calcium and vita-
min D. Patients suffering from severe renal dysfunction
(Creatine Clearance <30 ml/min) or patients needing
dialysis have a higher risk of hypocalcaemia. Severe vita-
min D deficiency in particular can predispose patients to
get severe symptomatic hypocalcaemia. That is why we
recommend checking the level and balancing out the
vitamin D deficiency before treatment with denosumab;
therefore, an analysis of the calcium level at 7–10 days
following treatment with denosumab should be consid-
ered; additionally, the cost of denosumab has to be men-
tioned (Table 4) and considered individually.
Results and discussion
Osteoporosis-associated fractures are of increasing im-
portance in trauma surgery. They can be accompanied
by significant morbidity and mortality for the patients
concerned. In Germany, only a small percentage of
patients suffering from osteoporosis receive treatment
according to [1, 50]. Algorithms for diagnosing and
treating osteoporosis suitable for daily use in traumatol-
ogy can contribute to improving the deficit in the com-
prehensive treatment of the disease as well as potentially
reduce osteoporosis-associated fractures and avoid fail-
ures with regard to the fracture fixation. Based on the
current guidelines of the DVO for diagnosing and treat-
ing osteoporosis, an algorithm for the diagnosis and
treatment of trauma surgical in-patients has been devel-
oped. The specific requirements according to DVO
guidelines to diagnose osteoporosis are laboratory diag-
nostics, clinical examinations and conducting a DXA.
The differences of our algorithm are that according to
the specific requirements for patients, who already
gained osteoporotic fractures of the proximal femur or
multiple vertebral body fractures I° (Genant) or singular
vertebral body fractures II–III° (Genant), the diagnosis
osteoporosis can be found with laboratory and radio-
graphic diagnostics and clinical examination. This pro-
ceeding allows to start a specific treatment of osteoporosis
meanwhile the surgical in-patient treatment. A pilot phase
in our clinic showed that training nursing staff how to use
the algorithm means significant relief for the doctor in
charge. On the basis of the listed inclusion criteria, all the
Table 4 Daily treatment costs of the specific medicinal treatment of osteoporosis
Group Compound Dose € € per day
Oral BP Alendronate 70 mg/week 34.09 (4 tablets) 1.14
Risedronate 35 mg/week 34.09 (4 tablets) 1.14
Ibandronate 150 mg/month 34.09 1.14
IV BP Zoledronatea 5 mg/year 548.14 1.50
Ibandronate 3 mg/3 months 141.42 1.57
SC Denosumab 60 mg/6 months 311.90 1.73
Osteoanabolic
Sc
Teriparatide 20 μg/day
pre-filled syringe
625.32
1 month
20.84
Source: Prices from the Rote Liste (German catalogue of drugs) 06-2014; BP ratiopharm©
aAs there are only generic products with 4 mg of Zoledronate available with different indications for its use, the price of the branded product “Aclasta” was listed
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patients were handed the enclosed risk questionnaire. If
osteoporosis was suspected, the nursing staff were then
able to prepare further diagnostics; DXA and basic labora-
tory tests were also initiated.
It is therefore possible to diagnose osteoporosis and
initiate treatment during the postoperative stay on a
trauma surgical ward. For the specific treatment of
osteoporosis with the oral bisphosphonate alendronate
and risedronate, cost-effective and evidence grade A
classified therapeutics are available. IV-bisphosphonates
are in principle good alternatives for oral application.
When patients are treated with zoledronate (5 mg/
year), which is not to be begun earlier than 14 days
after the operation, the next institution to provide
treatment (e.g. rehab clinic, geriatric ward) has to guar-
antee cooperation. There are no studies on the time of
treatment with denosumab following a fracture. Thus,
denosumab can be administered immediately after the
operation, taking the present data into account. It can
also be used if the patient suffers from renal insuffi-
ciency, and it causes no febrile reactions to infusions.
That is why we recommend this treatment after check-
ing calcium and 25-OH-vitamin D in patients with con-
traindications against oral bisphosphonates and/or a
severe course of the disease. Direct application during
the stay in hospital has to be considered according to
the relevant circumstances in the background. If the
course of osteoporosis is really severe (e.g. vertebral
body fractures during oral anti-resorptive treatment),
teriparatide is available as an osteoanabolic substance.
Risk, benefit, compliance, and cost all have to be con-
sidered individually in all drugs.
It is important to guarantee compliance immediately, in
the first year. To this end, not only are the care and heal-
ing of fractures to be monitored, but the patients and if
necessary their relatives are to be asked about their spe-
cific osteoporosis medication, at the latest during the out-
patient appointments for postoperative follow-up checks
of patients of trauma surgery. Only if the proper drugs are
taken or applied can the risk of fracture really be reduced.
Further investigations are required; to complement the
lack of a prospective validation of the algorithm, a pro-
spective clinical study is ongoing.
Conclusion for practice
 Osteoporosis is a frequent underlying disease in
elderly patients with fractures following low-energy
trauma which is of increasing importance for health
economics.
 The doctors in charge have a decisive function when
initiating diagnostics and the treatment of osteoporosis
to reduce further osteoporosis-associated fractures.
 A treatment algorithm suitable for daily use helps all
the surgeons on a trauma surgical ward to diagnose
and treat osteoporosis individually.
 The early diagnosis and treatment of osteoporosis
can reduce the current deficit in treatment and the
associated osteological deuteropathies as well as
contribute to allowing trauma surgery patients to
maintain their independence.
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